Related Experiment Videos
Fenretinide and its relation to cancer
1Department of Biochemistry and Molecular Biology, University of Leeds, Leeds, LS2 9JT, UK.
Cancer Treatment Reviews
|August 17, 1999
Summary
Fenretinide (4HPR) is a synthetic retinoid with fewer side-effects than natural retinoids. It effectively induces apoptosis, even in resistant cells, via unique pathways, showing promise as an anticancer drug.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Retinoids, vitamin A derivatives, exhibit anticancer and differentiation-inducing properties.
- Many retinoids cause significant side effects, limiting clinical applications.
- Fenretinide (4HPR) is a synthetic retinoid with a potentially improved side-effect profile.
Purpose of the Study:
- To review the mechanisms of action for fenretinide (4HPR).
- To summarize clinical trial outcomes for fenretinide.
- To evaluate fenretinide as a promising anticancer agent.
Main Methods:
- Review of existing literature on fenretinide's biological activity.
- Analysis of preclinical data regarding fenretinide's mechanism of action.
- Compilation and summary of data from fenretinide clinical trials.
Main Results:
- Fenretinide demonstrates anticancer activity and induces apoptosis.
- Fenretinide exhibits efficacy in cell lines resistant to other retinoids like all-trans retinoic acid (ATRA).
- Fenretinide appears to operate through distinct apoptotic pathways compared to classical retinoids.
Conclusions:
- Fenretinide is a promising anticancer drug with a favorable side-effect profile.
- Fenretinide's unique mechanism of action warrants further investigation.
- Clinical trials suggest potential therapeutic benefits of fenretinide.